LBRX (LB Pharmaceuticals) Ending Cash Position: $321.45 Mil (As of Mar. 2026)


LBRX LB Pharmaceuticals Inc LBRX
12 GF Score
Price $32.95
! 1 Warning Sign
View Full Analysis

What is LB Pharmaceuticals Ending Cash Position?

LB Pharmaceuticals LBRX -2.40% 12 Ending Cash Position is $321.45 Mil as of Mar. 2026. GuruFocus rates LBRX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

LB Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 was $321.45 Mil.

LB Pharmaceuticals's quarterly Ending Cash Position declined from Sep. 2025 ($270.26 Mil) to Dec. 2025 ($250.94 Mil) but then increased from Dec. 2025 ($250.94 Mil) to Mar. 2026 ($321.45 Mil).

LB Pharmaceuticals's annual Ending Cash Position increased from Dec. 2023 ($14.98 Mil) to Dec. 2024 ($23.48 Mil) and increased from Dec. 2024 ($23.48 Mil) to Dec. 2025 ($250.94 Mil).

LB Pharmaceuticals Ending Cash Position Related Terms

LB Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for LB Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LB Pharmaceuticals Ending Cash Position Chart

LB Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Ending Cash Position
21.40 14.98 23.48 250.94

LB Pharmaceuticals Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.33 14.73 270.26 250.94 321.45
LBRX
12GF Score
LB Pharmaceuticals Inc LBRX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LB Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

LB Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=23.476+227.467
=250.94

LB Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=250.943+70.509
=321.45

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $321.45 Mil mean?
LB Pharmaceuticals (LBRX) has a Ending Cash Position of $321.45 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on LB Pharmaceuticals and its competitors.
Is LB Pharmaceuticals' Ending Cash Position too high?
LB Pharmaceuticals' current Ending Cash Position is $321.45 Mil. Overall, LB Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LB Pharmaceuticals' Ending Cash Position compare to MRVI and SLDB?
LB Pharmaceuticals' Ending Cash Position of $321.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on LB Pharmaceuticals and its competitors. LB Pharmaceuticals's current Ending Cash Position is $321.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LB Pharmaceuticals stock overvalued right now?
LB Pharmaceuticals (LBRX) has a current Ending Cash Position of $321.45 Mil. The current Ending Cash Position is $321.45 Mil. LB Pharmaceuticals' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For LB Pharmaceuticals (LBRX), the current Ending Cash Position is $321.45 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LB Pharmaceuticals Business Description

Address One Pennsylvania Plaza, Suite 1025, New York, NY, USA, 10119
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
12GF Score

Get the complete analysis for LBRX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.95
Price